EMA Accelerates Review of Pancreatic Cancer Drug Daraxonrasib Through Phased Process

The European Medicines Agency (EMA) has initiated a phased review of daraxonrasib, an investigational oral RAS(ON) multi-selective inhibitor for pancreatic cancer. This accelerated assessment reflects the drug's potential to address a high unmet medical need in pancreatic ductal adenocarcinoma (PDAC), a form of cancer with a very low five-year survival rate.